Leukemia/MDS Clinical Trials
Category:Adult
Status:Active
Displaying Trial 1 - 30 of 65 in total
This randomized phase III trial studies combination chemotherapy with blinatumomab to see how well it works compared to induction chemotherapy alone in treating patients with newly diagnosed breakp...
Diagnosis: Leukemia/MDS
Phase: 3
Protocol Number: 15-709
Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)
The goal of this clinical research study is to compare how 2 different drugs, decitabine and azacitidine, when given on a shorter than standard dosing schedule, may help to control MDS. The safety ...
Diagnosis: Leukemia/MDS
Phase: 2
Protocol Number: 15-180
Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
In this research study we will start by looking for the highest dose of pyrimethamine that can be given safely to CLL patients without severe or unmanageable side effects. This dose will then be us...
Diagnosis: Leukemia/MDS
Phase: 1 / 2
Protocol Number: 09-421
This 2-stage, open-label study will evaluate safety and pharmacokinetics of ASTX727, as well as determine the dose for the study's second stage. In the second stage the selected dose will be c...
Diagnosis: Leukemia/MDS
Phase: 1 / 2
Protocol Number: 14-195
This research study is studying a targeted therapy known as GO-203-2C as a possible treatment for with acute myeloid leukemia (AML) both alone and in combination with decitabine. GO-203-2c targets ...
Diagnosis: Leukemia/MDS
Phase: 1 / 2
Protocol Number: 14-222
SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
This is a non-randomized, open-label, multi center study. A cycle of therapy is 5 consecutive days every 21 days for 6 or more cycles. Stage I will consist of a brief run-in period in which patient...
Diagnosis: Leukemia/MDS
Phase: 1 / 2
Protocol Number: 14-454
This is a non-randomized open label multi-center study. Patients who are in their first complete remission (CR) following induction therapy will be treated with SL-401, which will be administered a...
Diagnosis: Leukemia/MDS
Phase: 1 / 2
Protocol Number: 15-456
This Phase 1b/2 study is an open-label, randomized, multicenter trial to evaluate the safety and efficacy of oral AG-120 + SC azacitidine and oral A-221 + Subcutaneous (SC) azacitidine in subjects ...
Diagnosis: Leukemia/MDS
Phase: 1 / 2
Protocol Number: 16-057
This is a non-randomized open label multi-center study. Patients with high-risk myeloproliferative neoplasms (systemic mastocytosis [SM], advanced symptomatic hypereosinoophic disorder [PED], myelo...
Diagnosis: Leukemia/MDS
Phase: 1 / 2
Protocol Number: 16-149
Brentuximab Vedotin + Chemo for AML
This research study is a Phase I clinical trial. Phase I trials test the safety of an investigational drug or combination of drugs. These trials also try to define the appropriate dose of the inves...
Diagnosis: Leukemia/MDS
Phase: 1
Protocol Number: 13-040
This research study is evaluating drugs called bortezomib and lenalidomide as a possible treatment for myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The purpose of this research s...
Diagnosis: Leukemia/MDS
Phase: 1
Protocol Number: 14-213
This research study is evaluating a combination of two drugs, ibrutinib and obinutuzumab, as a possible treatment for Chronic Lymphocytic Leukemia (CLL).
Diagnosis: Leukemia/MDS
Phase: 1
Protocol Number: 15-283
MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age
This research study is evaluating drugs called Millennium 9708 (referred to as MLN9708) in combination with standard therapy for acute myeloid leukemia (AML) consisting of daunorubicin and cytarabi...
Diagnosis: Leukemia/MDS
Phase: 1
Protocol Number: 15-276
This is an open label, multicenter Phase 1 study to determine the MTD, dosing schedule and RP2D of IMGN779 when administered as mono-therapy to adult AML patients with CD33 -positive disease.
Diagnosis: Leukemia/MDS
Phase: 1
Protocol Number: 16-215
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects with relapsed or refractory acute myeloid leukemia
Diagnosis: Leukemia/MDS
Phase: 1
Protocol Number: 16-426
This phase I trial studies the side effects and best dose of ipilimumab when given together with decitabine in treating patients with myelodysplastic syndrome or acute myeloid leukemia that has ret...
Diagnosis: Leukemia/MDS
Phase: 1
Protocol Number: 17-718
This is a Phase 1, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of BLU-285, administered...
Diagnosis: Leukemia/MDS
Phase:
Protocol Number: 15-559
Study of INCB053914 in Subjects With Advanced Malignancies
This is an open-label, dose-escalation study of the PIM kinase inhibitor INCB053914 in subjects with advanced malignancies. The study will be conducted in 2 parts. Part 1 (dose escalation) will eva...
Diagnosis: Leukemia/MDS
Phase:
Protocol Number: 15-576
The purpose of this Phase I, multicenter, clinical trial is to evaluate the safety of AG-120 and AG-221 when given in combination with standard AML induction and consolidation therapy. The study pl...
Diagnosis: Leukemia/MDS
Phase:
Protocol Number: 15-527
A Collaborative Palliative and Oncology Care Model for Patients With Acute Myeloid Leukemia
This research study is evaluating the impact a collaborative palliative care and oncology team will have on the quality of life, symptoms, mood, and end of life outcomes of patients with acute myel...
Diagnosis: Leukemia/MDS
Phase:
Protocol Number: 16-439
This study will include a Phase 1 dose-finding portion (Cohorts A and B) and a four-arm expansion portion. The primary objectives of the study are to determine the maximum tolerated dose (MTD) and ...
Diagnosis: Leukemia/MDS
Phase:
Protocol Number: 16-326
This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of KTE-C19, an autologous anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in...
Diagnosis: Leukemia/MDS
Phase:
Protocol Number: 16-271
Intravenous BI 836826 in combination with ibrutinib in relapsed/refractory Chronic Lymphocytic Leukemia (CLL) patients who have been pre-treated with at least one prior line of systemic therapy, an...
Diagnosis: Leukemia/MDS
Phase:
Protocol Number: 16-278
Study of Regorafenib in Patients With Advanced Myeloid Malignancies
This research study is studying a drug as a possible treatment for advanced myeloid malignancies including AML (acute myeloid leukemia), MDS (myelodysplastic syndrome) and MPN (myeloproliferative n...
Diagnosis: Leukemia/MDS
Phase:
Protocol Number: 16-464
This research study is studying a cancer vaccine called Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) as a possible treatment for Acute Myelogenous Leukemia (AML). The interventions involved i...
Diagnosis: Leukemia/MDS
Phase:
Protocol Number: 16-593
This research study is studying a drug as a possible treatment for diagnosis of AML and high-risk MDS. The interventions involved in this study are: - SL-401 - Azacitidine
Diagnosis: Leukemia/MDS
Phase:
Protocol Number: 17-056
This study will evaluate the efficacy, safety, tolerability, and pharmacodynamics of entospletinib (GS-9973) when administered as monotherapy or in combination with chemotherapy in adults with acut...
Diagnosis: Leukemia/MDS
Phase:
Protocol Number: 17-012
Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia
This research study is studying a combination of two targeted therapies as a possible treatment for acute myeloid leukemia (AML) that has relapsed after initial treatment or did not fully respond. ...
Diagnosis: Leukemia/MDS
Phase:
Protocol Number: 17-099
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B ...
Diagnosis: Leukemia/MDS
Phase:
Protocol Number: 17-717
This research study is evaluating how a drug called lenalidomide, given in combination with the standard chemotherapy regimen of Mitoxantrone, Etoposide, and Cytarabine, commonly referred to as MEC...
Diagnosis: Leukemia/MDS
Phase:
Protocol Number: 16-574
